Amylyx Pharmaceuticals Income Statement (2021-2025) | AMLX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.28M0.55M26.56M84.55M108.41M111.86M126.61M88.64M1.02M0.42M26.23M
Cost of Revenue 0.17M2.82M5.28M5.58M5.22M9.36M5.95M0.01M
Gross Profit 0.38M23.74M79.27M102.83M106.65M117.25M82.70M1.01M
Operating items
Research & Development 6.86M10.93M12.85M5.67M21.46M24.26M24.91M22.81M24.19M29.04M30.04M44.91M36.61M23.35M21.24M22.89M22.12M27.22M19.86M
Selling, General & Administrative 6.00M7.66M10.35M14.92M26.35M29.99M29.94M40.84M44.01M43.39M48.72M52.24M57.76M21.65M17.83M17.10M15.68M15.64M16.17M
Other Operating Expenses 7.73M0.17M2.82M5.28M5.58M5.22M9.36M116.41M30.27M37.01M
Operating Expenses 12.87M18.59M23.20M28.32M47.81M54.25M55.03M66.48M73.48M78.02M83.97M106.52M210.77M75.26M76.08M39.99M37.80M42.86M36.03M
Operating Income -12.87M-18.59M-22.92M-28.32M-47.81M-54.25M-54.68M-44.59M-2.05M20.20M18.72M1.93M-122.13M-76.29M-75.66M-40.65M-37.80M-42.86M-36.03M
EBIT -12.87M-18.59M-22.92M-28.32M-47.81M-54.25M-54.68M-44.59M-2.05M20.20M18.72M1.93M-122.13M-76.29M-75.66M-40.65M-37.80M-42.86M-36.03M
Non-operating items
Interest & Investment Income 0.00M0.00M0.00M0.03M0.13M0.40M0.60M3.16M3.72M3.89M4.18M4.37M4.33M4.07M3.10M2.32M2.23M1.96M1.82M
Other Non Operating Income 0.26M-0.03M-0.23M-0.06M-0.02M-0.04M0.20M-0.69M-0.26M-0.08M-0.49M0.17M-0.75M-0.48M-0.14M0.16M-0.34M-0.55M-0.18M
Non Operating Income -1.66M-3.33M-0.23M-0.03M0.11M0.36M0.80M2.47M3.46M3.81M3.69M4.54M3.58M3.59M2.96M2.47M1.90M1.41M1.64M
Net income details
EBT -14.52M-21.92M-23.14M-28.34M-47.70M-53.89M-53.88M-43.23M1.40M24.01M22.41M6.48M-118.55M-72.70M-72.70M-38.18M-35.91M-41.44M-34.39M
Tax Provisions 0.15M0.20M-0.12M0.57M-0.17M1.93M1.52M1.97M0.24M-1.01M
Profit After Tax -14.52M-21.92M-23.14M-28.34M-47.85M-54.07M-53.76M-42.70M1.57M22.07M20.89M4.73M-118.79M-72.70M-72.70M-37.55M-35.91M-41.44M-34.39M
Income from Continuing Operations -14.52M-21.92M-23.14M-28.34M-47.85M-54.09M-53.76M-43.80M1.57M22.07M20.89M4.51M-118.79M-72.70M-72.70M-37.17M-35.91M-41.44M-34.39M
Consolidated Net Income -14.52M-21.92M-23.14M-28.34M-47.85M-54.09M-53.76M-43.80M1.57M22.07M20.89M4.51M-118.79M-72.70M-72.70M-37.17M-35.91M-41.44M-34.39M
Income towards Parent Company -14.52M-21.92M-23.14M-28.34M-47.85M-54.09M-53.76M-43.80M1.57M22.07M20.89M4.51M-118.79M-72.70M-72.70M-37.17M-35.91M-41.44M-34.39M
Net Income towards Common Stockholders -14.52M-21.92M-23.14M-28.34M-47.85M-54.09M-53.76M-43.80M1.57M22.07M20.89M4.51M-118.79M-72.70M-72.70M-37.17M-35.91M-41.44M-34.39M
Additional items
EPS (Basic) -2.33-3.41-3.42-4.15-0.93-0.93-0.92-0.620.020.330.310.07-1.75-1.07-1.07-0.54-0.42-0.46-0.37
EPS (Weighted Average and Diluted) -2.34-3.42-4.15-0.93-0.93-0.92-0.620.020.310.300.07-1.75-1.07-1.07-0.54-0.42-0.46-0.37
Shares Outstanding (Weighted Average) 55.22M55.22M55.22M57.86M58.53M58.53M58.53M66.26M66.72M67.38M67.38M67.52M67.78M68.01M68.08M68.55M88.60M89.14M89.17M
Shares Outstanding (Diluted Average) 6.43M6.76M6.59M51.60M58.28M58.53M58.50M70.86M69.99M67.85M68.02M68.09M85.70M89.14M93.33M
EBITDA -12.87M-18.59M-22.92M-28.32M-47.81M-54.25M-54.68M-44.59M-2.05M20.20M18.72M1.93M-122.13M-76.29M-75.66M-40.65M-37.80M-42.86M-36.03M
Tax Rate 0.23%8.05%6.77%30.40%2.65%